Modulation of lung cancer growth arrest and apoptosis by Phellinus Linteus

Molecular Carcinogenesis

Volumn 46, Issue 2, 2007, Pages 144-154

  Guo, Jinjin ^a   Zhu, Tongbo ^a   Collins, LeaAnn ^a   Xiao, Zhi Xiong J ^a   Kim, Sung Hoon ^b   Chen, Chang Yan ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Kyung Hee University   (South Korea)

Author keywords

Apoptosis; Growth arrest; Lung cancer; Phellinus Linteus

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DNA FRAGMENT; DOXORUBICIN; PHELLINUS LINTEUS EXTRACT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BASIDIOMYCETES; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; LUNG CANCER; LYMPHOCYTE ACTIVATION; MOUSE; MUSHROOM; NONHUMAN; PHELLINUS LINTEUS; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; BASIDIOMYCOTA; CELL DIVISION; CELL LINE; DOXORUBICIN; FLOW CYTOMETRY; G1 PHASE; LUNG NEOPLASMS; MICE;

BASIDIOMYCOTA; INONOTUS LINTEUS;

EID: 33847024849     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20275     Document Type: Article

References (43)

1. Oh GT, Han SB, Kim HM, Man MW, Yoo ID. Immunostimulating activity of Phellinus linteus extracts to B-lymphocyte. Arch Pharm Res 1992;15:379-381.
2. Song KS, Cho SM, Lee IK, et al. B-lymphocyte-stimulating polysaccharide from mushroom Phellinus linteus. Chem Pharm Bull 1995;43:2105-2108.
3. Han SB, Lee CW, Jeon YJ, et al. The inhibitory effect of polysaccharide isolated from Phellinus linteus on tumor growth and metastasis. Immunopharmacology 1999;41:157-164.
4. Borchers AT, Stern JS, Hackman RM, Keen CL, Gershwin EM. Minireview: Mushrooms, tumors and immunity. Soc Exp Biol Med 1999;221:281-293.
5. Lorenzen K, Anke T. Biologically active metabolites from basidiomycetes. Curr Org Chem 1998;2:329-364.
6. Reshetnikov SV, Wasser SP, Tan KK. Higher basidiomycetes as a source of antitumour and immunostimulating polysaccharides (Review). Int J Med Mushrooms 2001;3:361-394.
7. Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotech 2002:60:258-274.
8. Chihara G, Maeda Y, Hamuro J, Sasaki T, Fumiko F. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes. Nature 1969;222:687-688.
9. Chung KS, Choi EC, Kim BK, Kim YS, Park YK. The constituents and culture of Korean Basidiomycetes: Antitumor polysaccharides from the cultured mycelia of some Basidiomycetes. Arch Pharm Res 1982;5:17-20.
10. Cun Z, Mizuno T, Ito H, Shimura K, Sumiya T, Kawade M. Antitumor activity and immunological property of polysaccharides from the mycelium of liquid-cultured Grifola frondosa. J Jpn Soc Food Sci Technol 1994;41:724-732.
11. Carbone DP, Minna JD. The molecular genetics of lung cancer. Adv Intern Med 1992;37:1 53-171.
12. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. Cancer J Clin 1998;48:6-29.
13. Tuveson DA, Jacks T. Modeling human lung cancer in mice: Similarities and shortcomings. Oncogene 1999;18:5318-5324.
14. Bos JL. ras Oncogenes in human cancer: A review. Cancer Res 1990;49:4682-4689.
15. Rodenhuis S, van de Wetering MI, Mooi WJ, Evers SG, van Zamdwijk N, Bos JL. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987;317:929-935.
16. Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, van Wagenaar SS. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988;48:5738-5741.
17. Mills NE, Fishman CL, Rom WN, Dubin N, Jacobson DR. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 1995;55:1444-1447.
18. Arber N, Sutter T, Miyake M, et al. Increased expression of cyclin D1 and the Rb tumor suppressor gene in c-K-ras transformed rat enterocytes. Oncogene 1996;12:1903-1908.
19. Filmus J, Rubles AI, Shi W, Wong MJ, Colombo LL, Conti CJ. Induction of cyclin D1 overexpression by activated ras. Oncogene 1994;9:3629-3633.
20. Liu J-J, Chao J-R, Jiang M-C, Ng S-Y, Yen JJ, Yen HEY. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. Mol Chem Biol 1995;15:3654-3663.
21. Lovec H, Sewing A, Lucibello FC, Muller R, Moroy T. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: Link between cell cycle control and malignant transformation. Oncogene 1994;9:323-326.
22. Dyson N. The regulation of E2F by pRB-family proteins. Gene Dev 1998;12:2245-2262.
23. Abbas AK. Die and let live: Eliminating dangerous lymphocytes. Cell 1996;84:655-657.
24. Meier P, Evan G. Dying like flies. Cell 1998;95:295-298.
25. Green DR. Apoptotic pathways: The roads to ruin. CeI 1998;94:695-698.
26. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Vallach D. A novel protein that interacts, with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995;270:7795-7798.
27. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-512.
28. Enari M, Hug H, Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995;375:78-81.
29. Enari M, Talanian RV, Wong WW, Nagata S. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 1996;380:723-726.
30. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: Requirement for dATP and Cytochrome c. Cell 1996;86:147-157.
31. Chinnaiyan AM, O'Rourke K, Lane BR, Dixit VM. Interaction of CED-4 with CED-3 and CED-9: A molecular framework for cell death. Science 1997;275:1122-1126.
32. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997;18:44-51.
33. Li F, Srinivasan A, Wang Y, Amstrong RC, Tomaselli KJ, Fritz IC. Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release. J Biol Chem 1997;272:30299-30305.
34. Ma P, Magut M, Chen X, Chen C-Y. p53 is necessary for the apoptotic response mediated by a transient increase of Ras activity. Mol Cell Biol 2002;22:2928-2938.
35. Denis GV, Yu Q, Ma P, Deeds L, Faller DV, Chen C-Y. Bcl-2, via its BH4 domain, blocks apoptotic signaling mediated by mitochondrial Ras. J Biol Chem 2003;278:5775-5785.
36. Yu J, Tian S, Metheny-Barlow L, et al. Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res 2001;89:1161-1167.
37. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL induced apoptosis in breast cell lines. Cancer Res 1999;59:734-741.
38. Mizutani Y, Yoshida O, Miki T, Bonavida B. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. Clin Cancer Res 1999;5:2605-2612.
39. Yamanaka T, Shiraki K, Sugimoto K, et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 2000;32:482-490.
40. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to TRAIL-mediated caspase-8 activation and apoptosis. Cancer Res 2001;61:1645-1651.
41. Wu S-S, Kakehi Y, Mizutani Y, et al. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int J Oncol 2002;20:949-954.
42. Romijn JC, Verkoelen CF, Schroeder FH. Determination of the growth rate of human prostatic cells in primary culture by a morphometric technique. Cell Biol Int Rep 1984;8:363-371.
43. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-4445.